Virtual Library
Start Your Search
Homayemem Weli
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-98 - Outcomes of Non-Small Cell Lung Cancer Patients with Brain Metastasis Treated by Whole Brain Radiotherapy, a Single Institution Experience (Now Available) (ID 116)
08:00 - 18:00 | Author(s): Homayemem Weli
- Abstract
Background
Whole brain radiotherapy (WBRT) is predominantly used in the treatment of brain metastasis but recent data suggests that it does not significantly contribute to improved overall survival in patients. This study was carried out to review our practice by assessing the survival outcome for NSCLC patients with brain metastasis treated with WBRT in relation to the QUARTZ trial data (Mulvena et al, 2016).
Method
A retrospective study of such patients over a period of 12 months was carried by obtaining data from
electronic record systems and radiotherapy records. Data demographics and analysis of overall survival were
calculated and comparison was made with literature findings.
Result
Over 12 months 39 patients with brain metastasis had received WBRT (30G in 10# or 20G in 5#). 68% (n=29) were of NSCLC origin with a gender ratio of 1:1. The average age at diagnosis of NSCLC was 67.8 and 70 years for males and females respectively. Majority of NSCLCC patients treated with WBRT had a WHO performance status (PS) of 1(41.3%, n=12) or 0 (27.5%, n=8). Mean survival following treatment with WBRT was 16.7 weeks. The median survival was 10 weeks and average ages of death in the female and male patients were 67.8 and 70 years respectively. An incidental finding of longer survival (31.8 weeks) was noted in patients treated with 30Gray and 10 fractions compared with those treated with 20Gray and 5# (9.5 weeks). 43.8% of those receiving 30Gray and 10 fractions were of PS 0 in contrast with 14.2% of those receiving 20G in 5#.
Conclusion
The median survival in our patients treated with WBRT was comparable to that obtained in the QUARTZ study (9.2 weeks in those who received WBRT and optimal supportive care). Although a retrospective study, it is suggestive of an above average survival outcome in our practice when compared to the multinational QUARTZ study. The incidental observation of higher survival in the group who received higher RT dose and fraction may be explained by clinical decision influencing RT categorisation due to the fact that patients with better performance status are more likely to tolerate higher doses of RT and be given same.
